glp-1 receptor agonists alternatives to ozempic Type 2 diabetes: New pill now available in the U.S Trends in Glucagon-Like Peptide 1
Description
Mediators Inflamm
Kirkegaard H, Bliddal M, Stvring H, Rasmussen KM, Gunderson EP, Kber L, et al
Treatment Decision-Making Treatment decision-making can be guided by the different mechanisms of action of AOMs to ascertain the suitability of the therapy for the individual patient
doi: 10.4103/1673-5374.320965 [DOI] [PMC free article] [PubMed] [Google Scholar] 99
The incretin agonist I-M-150846 revealed a complete loss of function at GLP-1R while retaining GIPR activity (Table 1)
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al
